10-Year Return on Invested Incremental Capital (10-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 10-year.
Lifecore Biomedical's 10-Year ROIIC % for the quarter that ended in May. 2025 was 31.33%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Lifecore Biomedical's 10-Year ROIIC % or its related term are showing as below:
LFCR's 10-Year ROIIC % is ranked better than 82.91% of 860
companies
in the Drug Manufacturers industry
Industry Median: 4.41
vs LFCR: 31.33
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Lifecore Biomedical 10-Year ROIIC % Related Terms
Lifecore Biomedical 10-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Lifecore Biomedical's 10-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LFCR vs ANIK, DERM, ASRT: 10-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Lifecore Biomedical's 10-Year ROIIC %, along with its competitors' market caps and 10-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lifecore Biomedical 10-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Lifecore Biomedical's 10-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Lifecore Biomedical's 10-Year ROIIC % falls into.
Lifecore Biomedical's 10-Year ROIIC % for the quarter that ended in May. 2025 is calculated as:
10-Year ROIIC %
=
10-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
10-Year Incremental Invested Capital**
=
( -12.006 (May. 2025) - 11.8002712 (May. 2015) )
/
( 216.126 (May. 2025) - 292.117 (May. 2015) )
=
-23.8062712
/
-75.991
=
31.33%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 10-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Lifecore Biomedical (LFCR) has a 10-Year ROIIC % of 31.33 as of May. 2025. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Lifecore Biomedical and its competitors. According to the industry distribution chart, Lifecore Biomedical ranks #147 out of 860 companies in the Drug Manufacturers industry, placing it in the top 17.1%.
Is Lifecore Biomedical's 10-Year ROIIC % too high?
Lifecore Biomedical's current 10-Year ROIIC % is 31.33. The Drug Manufacturers industry median 10-Year ROIIC % is 4.41. Lifecore Biomedical's value of 31.33 is 610.4% above this industry median. Based on the distribution chart, Lifecore Biomedical ranks #147 out of 860 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Lifecore Biomedical has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Lifecore Biomedical's 10-Year ROIIC % compare to ANIK and DERM?
According to the Drug Manufacturers industry distribution chart, Lifecore Biomedical ranks #147 out of 860 companies for 10-Year ROIIC %. This places Lifecore Biomedical in the top 17% of its industry — outperforming the majority of peers. The industry median 10-Year ROIIC % is 4.41. Lifecore Biomedical's value of 31.33 is 610.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year ROIIC % for a Drug Manufacturers company?
The median 10-Year ROIIC % among Drug Manufacturers companies is 4.41, based on 860 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lifecore Biomedical's current 10-Year ROIIC % of 31.33 is 610.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year ROIIC % mean?
A high 10-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 10-Year ROIIC % measures the change in earnings as a percentage of change in investment over 10-year. View historical data on Lifecore Biomedical and its competitors. For the Drug Manufacturers industry, the median 10-Year ROIIC % is 4.41 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lifecore Biomedical's current 10-Year ROIIC % is 31.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lifecore Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Lifecore Biomedical (LFCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.48, compared to a current price of $4.74 — trading 26.9% below its estimated fair value. The current 10-Year ROIIC % is 31.33 and 610.4% above the Drug Manufacturers industry median of 4.41. Lifecore Biomedical's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year ROIIC % calculated?
10-Year ROIIC % is calculated from a company's financial statements. For Lifecore Biomedical (LFCR), the current 10-Year ROIIC % is 31.33 as of May. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lifecore Biomedical (LFCR) Overvalued in 2026?
Based on GuruFocus' analysis, Lifecore Biomedical stock appears to be undervalued.
The current stock price of $4.74 is trading 26.9% below its estimated GF Value™ of $6.48.
GuruFocus considers Lifecore Biomedical to be Modestly Undervalued.
Key valuation signals for LFCR:
10-Year ROIIC %: 31.33
GF Value™: $6.48 vs. price of $4.74 (26.9% below fair value)
Industry Position: 610.4% above the Drug Manufacturers median (#147 of 860)
No single metric tells the full story. See the LFCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) that provides services in the development, fill, and finish of complex sterile injectable pharmaceutical products in syringes, vials, and cartridges. The group recognizes revenue in two different product categories, CDMO and HA manufacturing.
55GF Score
Get the complete analysis for LFCR
10-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LFCR has been successfully added to your 
